AUDENTES THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • January 4th, 2016 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made and entered into as of October 8, 2015 by and among Audentes Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” any subsequent investor that becomes a party to this Agreement in accordance with Section 7.14 hereof and any holder of a Lender Warrant that becomes a party to this Agreement in accordance with Section 7.14 hereof.
OFFICE LEASE BY AND BETWEEN a California limited partnership AS LANDLORD AND AUDENTES THERAPEUTICS, INC., a Delaware corporation AS TENANT PREMISES: San Francisco, CaliforniaOffice Lease • January 4th, 2016 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
THIS OFFICE LEASE (this “Lease”) is made as of the 17th day of October, 2013, by and between 101 Montgomery Street Co., a California limited partnership (“Landlord”), and Audentes Therapeutics, Inc., a Delaware Corporation (“Tenant”).
COLLABORATIVE DEVELOPMENT AGREEMENT No. 013135-1MTUB-00Collaborative Development Agreement • January 4th, 2016 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • England and Wales
This COLLABORATIVE DEVELOPMENT AGREEMENT (the “Agreement”), effective as of January 24, 2014 (the “Effective Date”), is made by and between Audentes Therapeutics, Inc., a Delaware corporation, having a place of business at 101 Montgomery Street, Suite 2650, San Francisco, CA 94104, USA (“Audentes”) and Genethon, a French not-for-profit organization organised under the French law of July 1, 1901, having a principal place of business at 1bis rue de l’Internationale, 91002 EVRY Cedex, France (“Genethon”).
LICENSE AGREEMENTLicense Agreement • January 4th, 2016 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This LICENSE AGREEMENT (“Agreement”) is entered into as of November 3, 2015 (“Effective Date”) by and between REGENXBIO Inc., a corporation organized under the laws of the State of Delaware, with offices at 9712 Medical Center Drive, Suite 100, Rockville, MD 20850 (“Licensor”), and Audentes Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with offices at 101 Montgomery Street, Suite 2650, San Francisco, California, 94104 (“Licensee”). Licensor and Licensee are hereinafter referred to individually as a “Party” and collectively as the “Parties.”
SUBLEASESublease • January 4th, 2016 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Lease dated May 22, 1997, for reference purposes only, is by and between JOHN C. NICKEL (“Lessor”) and ATHENA NEUROSCIENCES, INC., a Delaware corporation (“Lessee”).
OFFICE LEASEOffice Lease • January 4th, 2016 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
Access Laws: The Americans With Disabilities Act of 1990 (including the Americans with Disabilities Act Accessibility Guidelines for Building and Facilities) and all other Governmental Requirements relating to the foregoing.
LICENSE AGREEMENTLicense Agreement • January 4th, 2016 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This LICENSE AGREEMENT (“Agreement”) is entered into as of November 3, 2015 (“Effective Date”) by and between REGENXBIO Inc., a corporation organized under the laws of the State of Delaware, with offices at 9712 Medical Center Drive, Suite 100, Rockville, MD 20850 (“Licensor”), and Audentes Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with offices at 101 Montgomery Street, Suite 2650, San Francisco, California, 94104 (“Licensee”). Licensor and Licensee are hereinafter referred to individually as a “Party” and collectively as the “Parties.”
LICENSE AGREEMENTLicense Agreement • January 4th, 2016 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This License Agreement (“Agreement”) is made as of September 26, 2014 (the “Effective Date”) by and between the Fondazione Salvatore Maugeri, an organization established under the laws of Italy (“FSM”), and Cardiogen Sciences, Inc., a Delaware corporation (“Cardiogen”). Each of FSM and Cardiogen are referred to herein as “Party” and together as the “Parties.”
LICENSE AGREEMENTLicense Agreement • January 4th, 2016 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This LICENSE AGREEMENT (“Agreement”) is entered into as of July 9th, 2013 (“Effective Date”) by and between ReGenX Biosciences, LLC (formerly known as ReGenX, LLC), a limited liability company organized under the laws of the State of Delaware, with offices at 750 17th Street, NW, Suite 1100, Washington, DC 20006 (“Licensor”), and Audentes Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with offices at [*] San Francisco, California, 94115 (“Licensee”). Licensor and Licensee are hereinafter referred to individually as a “Party” and collectively as the “Parties.”
EXCLUSIVE LICENSE AGREEMENT WITH KNOW-HOW Agreement No: A13169Exclusive License Agreement • January 4th, 2016 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • Florida
This Agreement is effective as of July 28, 2015 (the “Effective Date”) between the University of Florida Research Foundation, Incorporated (hereinafter called “UFRF”), a nonstock, nonprofit Florida corporation, and Audentes Therapeutics, Inc. (hereinafter called “Licensee”), a Delaware corporation having a principal address at 101 Montgomery Street, Suite 2650, San Francisco, CA 94104.
